1 Correction to: Clin Drug Investig https://doi.org/10.1007/s40261-017-0615-z
In the original publication, the abstract, conclusion was incorrectly published.
Abstract, Conclusions which previously read:
Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy when used as monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.
Should read:
Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy in monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.
The original article was corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1007/s40261-017-0615-z.
Rights and permissions
About this article
Cite this article
Barrachina-Martínez, I., Vivas-Consuelo, D. & Piera-Balbastre, A. Correction to: Budget Impact Analysis of Brivaracetam Adjunctive Therapy for Partial-Onset Epileptic Seizures in Valencia Community, Spain. Clin Drug Investig 38, 365 (2018). https://doi.org/10.1007/s40261-018-0630-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-018-0630-8